Patents by Inventor Katherine E. Lewis

Katherine E. Lewis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-CSF1R Antibody and Anti-PD-1 Antibody Combination Therapy for Cancer
    Publication number: 20230212299
    Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.
    Type: Application
    Filed: December 21, 2022
    Publication date: July 6, 2023
    Applicants: Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
    Inventors: Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Katherine E. Lewis
  • Combination Anti-CSF1R and Anti-PD-1 Antibody Combination Therapy for Pancreatic Cancer
    Publication number: 20230192870
    Abstract: The present invention relates to methods of treating pancreatic cancer with particular dosage regimes of antibodies that bind colony stimulating factor 1 receptor (CSF1R) (e.g. cabiralizumab) in combination with antibodies that bind programmed cell death 1 (PD-1) (e.g. nivolumab).
    Type: Application
    Filed: July 14, 2022
    Publication date: June 22, 2023
    Applicants: Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
    Inventors: Katherine E. Lewis, Serena Kimi Perna, Michael Carleton, Ke Xu, Penny Phillips, Dimple Pandya, Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Janine Powers, Ernestine Lee
  • Anti-CSF1R antibody and anti-PD-1 antibody combination therapy for selected cancers
    Patent number: 11566076
    Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.
    Type: Grant
    Filed: March 4, 2020
    Date of Patent: January 31, 2023
    Assignees: Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
    Inventors: Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Katherine E. Lewis
  • Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancer
    Patent number: 11421034
    Abstract: The present invention relates to methods of treating pancreatic cancer with particular dosage regimes of antibodies that bind colony stimulating factor 1 receptor (CSF1R) (e.g. cabiralizumab) in combination with antibodies that bind programmed cell death 1 (PD-1) (e.g. nivolumab).
    Type: Grant
    Filed: September 12, 2018
    Date of Patent: August 23, 2022
    Assignees: Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
    Inventors: Katherine E. Lewis, Serena Kimi Perna, Michael Carleton, Ke Xu, Penny Phillips, Dimple Pandya, Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Janine Powers, Ernestine Lee
  • USE OF ANTI-CTLA-4 ANTIBODIES WITH ENHANCED ADCC TO ENHANCE IMMUNE RESPONSE TO A VACCINE
    Publication number: 20220127363
    Abstract: The present invention provides methods of enhancing immune response to a vaccine using variant forms of anti-CTLA-4 antibodies having enhanced ADCC activity. Variant anti-CTLA-4 antibodies for use in the present invention include nonfucosylated ipilimumab.
    Type: Application
    Filed: January 13, 2022
    Publication date: April 28, 2022
    Inventors: John T. LOFFREDO, Katherine E. LEWIS, Robert F. GRAZIANO, Alan J. KORMAN
  • Anti-LAG-3 Antibodies to Treat Hematological Malignancies
    Publication number: 20210122820
    Abstract: Provided are methods for clinical treatment of hematological malignancies, such as relapsed or refractory chronic lymphocytic leukemia or lymphoma using an anti-LAG-3 antibody. Particular malignancies include, e.g., chronic lymphocytic leukemia (CLL), Hodgkin lymphoma (HL), or non-Hodgkin lymphoma (NHL).
    Type: Application
    Filed: September 9, 2020
    Publication date: April 29, 2021
    Inventors: Andres A. GUTIERREZ, Joseph GROSSO, Christopher Mark HILL, Mark J. SELBY, Katherine E. LEWIS
  • Combination Anti-CSF1R and Anti-PD-1 Antibody Combination Therapy for Pancreatic Cancer
    Publication number: 20210009697
    Abstract: The present invention relates to methods of treating pancreatic cancer with particular dosage regimes of antibodies that bind colony stimulating factor 1 receptor (CSF1R) (e.g. cabiralizumab) in combination with antibodies that bind programmed cell death 1 (PD-1) (e.g. nivolumab).
    Type: Application
    Filed: September 12, 2018
    Publication date: January 14, 2021
    Applicants: Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
    Inventors: Katherine E. Lewis, Serena Kimi Perna, Michael Carleton, Ke Xu, Penny Phillips, Dimple Pandya, Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Janine Powers, Ernestine Lee
  • Anti-CSF1R Antibody and Anti-PD-1 Antibody Combination Therapy for Cancer
    Publication number: 20200299392
    Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.
    Type: Application
    Filed: March 4, 2020
    Publication date: September 24, 2020
    Applicants: Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
    Inventors: Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Katherine E. Lewis
  • Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer
    Patent number: 10618967
    Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.
    Type: Grant
    Filed: January 9, 2019
    Date of Patent: April 14, 2020
    Assignees: Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
    Inventors: Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Katherine E. Lewis
  • Treating inflammation with IL-17/IL-23 bispecific antibodies
    Patent number: 10562967
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: February 18, 2020
    Assignee: ZymoGenetics, Inc.
    Inventors: Katherine E. Lewis, Scott R. Presnell, Steven D. Levin, Robert Mabry, Stephen R. Jaspers, Monica J. Huber
  • USE OF ANTI-CTLA-4 ANTIBODIES WITH ENHANCED ADCC TO ENHANCE IMMUNE RESPONSE TO A VACCINE
    Publication number: 20190382490
    Abstract: The present invention provides methods of enhancing immune response to a vaccine using variant forms of anti-CTLA-4 antibodies having enhanced ADCC activity. Variant anti-CTLA-4 antibodies for use in the present invention include nonfucosylated ipilimumab.
    Type: Application
    Filed: February 27, 2018
    Publication date: December 19, 2019
    Inventors: John T. LOFFREDO, Katherine E. LEWIS, Robert F. GRAZIANO, Alan J. KORMAN
  • Anti-CSF1R Antibody and Anti PD-1 Antibody Combination Therapy for Cancer
    Publication number: 20190202921
    Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.
    Type: Application
    Filed: January 9, 2019
    Publication date: July 4, 2019
    Applicants: Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
    Inventors: Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Katherine E. Lewis
  • Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer
    Patent number: 10221244
    Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: March 5, 2019
    Assignees: Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
    Inventors: Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Katherine E. Lewis
  • Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors
    Patent number: 10081681
    Abstract: Provided are methods for clinical treatment of tumors (e.g., advanced solid tumors) using an anti-LAG-3 antibody in combination with an anti-PD-1 antibody.
    Type: Grant
    Filed: September 18, 2014
    Date of Patent: September 25, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Alan J. Korman, Nils Lonberg, David J. Fontana, Andres A. Gutierrez, Mark J. Selby, Katherine E. Lewis
  • TREATING INFLAMMATION WITH IL-17/IL-23 BISPECIFIC ANTIBODIES
    Publication number: 20180251541
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.
    Type: Application
    Filed: May 8, 2018
    Publication date: September 6, 2018
    Inventors: Katherine E. Lewis, Scott R. Presnell, Steven D. Levin, Robert Mabry, Stephen R. Jaspers, Monica J. Huber
  • ANTI-LAG-3 ANTIBODIES TO TREAT HEMATOLOGICAL MALIGNANCIES
    Publication number: 20180244773
    Abstract: Provided are methods for clinical treatment of hematological malignancies, such as relapsed or refractory chronic lymphocytic leukemia or lymphoma using an anti-LAG-3 antibody. Particular malignancies include, e.g., chronic lymphocytic leulcemia (CLL), Hodgkin lymphoma (HL), or non-Hodgkin lymphoma (NHL).
    Type: Application
    Filed: February 9, 2018
    Publication date: August 30, 2018
    Inventors: Andres A. GUTIERREZ, Joseph GROSSO, Christopher Mark HILL, Mark J. SELBY, Katherine E. LEWIS
  • TREATMENT OF CANCER USING A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND IL-6
    Publication number: 20180214547
    Abstract: This disclosure provides a method for treating a subject afflicted with a cancer, which method comprises administering to the subject therapeutically effective amounts of: (a) an anti-cancer agent which is an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity; and, (b) IL-6.
    Type: Application
    Filed: July 8, 2016
    Publication date: August 2, 2018
    Inventor: Katherine E. Lewis
  • Use of an IL-17/IL-23 bispecific antibody for treating inflammation
    Patent number: 9994634
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and IL-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: June 12, 2018
    Assignee: ZYMOGENETICS, INC.
    Inventors: Katherine E. Lewis, Scott R. Presnell, Steven D. Levin, Robert Mabry, Stephen R. Jaspers, Monica J. Huber
  • ANTI-CSF1R ANTIBODY AND ANTI PD-1 ANTIBODY COMBINATION THERAPY FOR CANCER
    Publication number: 20180094067
    Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.
    Type: Application
    Filed: August 18, 2017
    Publication date: April 5, 2018
    Applicants: Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
    Inventors: Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Katherine E. Lewis
  • Anti-CSFR1 antibody and anti PD-1 antibody combination therapy for cancer
    Patent number: 9765147
    Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: September 19, 2017
    Assignees: Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
    Inventors: Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Katherine E. Lewis